Physician profile
Scott Thomas Strait
NPI 1235626318
$3,069.08
in general payments reported to CMS, 2019-2025
34 companies · $315 in 2025
The $315 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.86 · 2021: $342 · 2022: $969 · 2023: $869 · 2024: $564 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,747.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $777.99 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $314.30 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $296.84 | 2022-2024 | Mounjaro, Jardiance |
| Abbott Laboratories | $295.71 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $187.02 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $164.60 | 2022-2024 | Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $107.15 | 2022-2025 | |
| Glaxosmithkline, LLC. | $87.26 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $71.35 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $69.83 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.80 | 2021-2024 | Jardiance, Tradjenta, Synjardy |
| Amarin Pharma, INC. | $57.03 | 2021-2022 | |
| Amgen INC. | $49.90 | 2021-2023 | Evenity, Prolia, Otezla |
| Merck Sharp & Dohme LLC | $44.41 | 2022-2023 | Belsomra, Steglatro, Steglujan |
| Janssen Pharmaceuticals, INC | $42.44 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $41.12 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $34.52 | 2022-2025 | |
| Daiichi Sankyo INC. | $34.52 | 2021-2024 | Injectafer |
| Almatica Pharma LLC | $33.83 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.94 | 2022 | |
| Exact Sciences Corporation | $32.32 | 2023 | Cologuard Collection Kit |
| Dexcom, INC. | $31.04 | 2022-2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $29.46 | 2021 | |
| Avanir Pharmaceuticals, INC. | $21.18 | 2022 | |
| Corium, LLC | $17.67 | 2022 | |
| Sanofi Pasteur INC. | $17.30 | 2023 | |
| Phathom Pharmaceuticals, INC. | $16.88 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $15.29 | 2023 | Quviviq |
| Renalytix Ai, INC. | $14.90 | 2022 | |
| Inspire Medical Systems, INC. | $14.64 | 2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $13.53 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.57 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.49 | 2022 | |
| Eisai INC. | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Strait listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.